Diabetes Mellitus, Type II
Metabolic Diseases
3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
HM
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstraZenecatriple combination therapy
Hua MedicineHM-002-1005
Eli Lilly and CompanyLY2189265
Clinical Trials (3)
Total enrollment: 174 patients across 3 trials
Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes
Start: Dec 2016Est. completion: Dec 2019104 patients
Phase 3Unknown
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
Start: Apr 2024Est. completion: Sep 202440 patients
Phase 1Completed
A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.
Start: Feb 2011Est. completion: Aug 201130 patients
Phase 1Completed
Related Jobs in Metabolic Diseases
Manager, Patient Safety and Pharmacovigilance Operations
Kailera Therapeutics
Waltham, Massachusetts
8h ago
Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV
Amgen
California - San Francisco, US
Yesterday
(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)
Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago
Computational Chemist
Topos Bio
San Francisco Office
2d ago
Associate Director, Legal Operations & Contracts Management
Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr
Application & Integration Architect
Roche
Indianapolis
5d ago
$106K - $196K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space